What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Melanoma, Surgery, Gastroenterology and Clinical endpoint.
The study of Internal medicine is intertwined with the study of Oncology in a number of ways.
His Melanoma research is multidisciplinary, incorporating perspectives in Nivolumab and Clinical trial.
His Gastroenterology study combines topics from a wide range of disciplines, such as Phases of clinical research, Talimogene laherparepvec and Hazard ratio.
His work deals with themes such as Carcinoma and Survival analysis, which intersect with Clinical endpoint.
His work on Cobimetinib as part of general Vemurafenib research is often related to Homogeneous, thus linking different fields of science.
His most cited work include:
- Inhibition of mutated, activated BRAF in metastatic melanoma. (2901 citations)
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations (1946 citations)
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib (1661 citations)
What are the main themes of his work throughout his whole career to date?
Igor Puzanov mostly deals with Internal medicine, Oncology, Melanoma, Cancer research and Ipilimumab.
Igor Puzanov has included themes like Gastroenterology and Surgery in his Internal medicine study.
His Oncology study integrates concerns from other disciplines, such as Cancer, Nivolumab, Clinical endpoint and Phases of clinical research.
He does research in Melanoma, focusing on Vemurafenib specifically.
His research in Vemurafenib intersects with topics in Trametinib and Pathology.
The Ipilimumab study combines topics in areas such as Immune checkpoint and Refractory.
He most often published in these fields:
- Internal medicine (66.24%)
- Oncology (46.95%)
- Melanoma (40.51%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (66.24%)
- Oncology (46.95%)
- Melanoma (40.51%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Melanoma, Pembrolizumab and Cancer are his primary areas of study.
His work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Clinical endpoint.
The concepts of his Oncology study are interwoven with issues in Biomarker, Immune system, Immune checkpoint inhibitors and Phases of clinical research.
His Melanoma research includes elements of Immune checkpoint, Clinical trial, MEK inhibitor, Talimogene laherparepvec and Adjuvant therapy.
His studies deal with areas such as Axitinib and Renal cell carcinoma as well as Pembrolizumab.
He works mostly in the field of Cancer, limiting it down to concerns involving Cancer research and, occasionally, Receptor, T cell and Antigen presentation.
Between 2018 and 2021, his most popular works were:
- COVID-19 and Cancer: a Comprehensive Review. (88 citations)
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium (54 citations)
- Anti-IL6R role in treatment of COVID-19-related ARDS. (41 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Oncology, Adverse effect, Melanoma and Cancer.
His work on Internal medicine deals in particular with Immunotherapy, Pembrolizumab, Cohort, Vemurafenib and Nivolumab.
His research integrates issues of Immune checkpoint, Phases of clinical research, Immune system, Immune checkpoint inhibitors and Biomarker in his study of Oncology.
Anti pd 1, Carcinoid tumors, Neuroendocrine tumors and Clinical endpoint is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Adverse effect.
His Melanoma research incorporates themes from Clinical trial, MEK inhibitor, Talimogene laherparepvec, Surgical oncology and Adjuvant therapy.
His biological study spans a wide range of topics, including Lineage, Cancer research and Medical history.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
